Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker LLP) - Citizen Petition

This Other document was issued by the Food and Drug Administration (FDA)

For related information, Open Docket Folder


Content

See attached file(s)

Attachments

 (26)

Purdue Pharma L P Kleinfeld Kaplan and Becker LLP Citizen Petition

View Attachment:
Authors: cder
 

Exhibit 1 Coplan et al National Changes in OxyContin Other Oxycodone and Heroin Exposures Reported to Poison Centers With...

View Attachment:

Exhibit 2 Coplan et al Changes After Reformulation of Extended Release Oxycodone in Calls to US Poison Centers for Oxycodone and...

View Attachment:

Exhibit 3 Coplan et al Effects of Reformulated OxyContin on Opioid Abuse in the National Poison Data System American Pain...

View Attachment:

Exhibit 4 Severtson et al Decline in Rates of Abuse of Extended Release ER Oxycodone Following the Introduction of a Reformulated...

View Attachment:

Exhibit 5 Severtson et al Reduced Abuse and Diversion Following the Reformulation of OxyContin RADARS

View Attachment:

Exhibit 6 Severtson et al Reduction in OxyContin Diversion Cases Following the Introduction of Reformulated OxyContin

View Attachment:

Exhibit 7 Davis et al Reduction in Extended Release Oxycodone Diversion Rates Following The Introduction of A Reformulated ER...

View Attachment:

Exhibit 8 Bucher Bartelson et al A Comparison of the Street Price of Original and Reformulated ER Oxycodone

View Attachment:
Publication Reference: International Association for the Study of Pain
 

Exhibit 9 Severtson et al A Comparison of the Street Price of Original and Reformulated OxyContin and Immediate Release IR...

View Attachment:

Exhibit 10 Chilcoat et al Impact of Reformulated OxyContin on Rates of Abuse Through Oral and non Oral Routes Among Individuals...

View Attachment:
Agency Notes: extra pages for readabilty
 

Exhibit 11 Cassidy et al Change in Routes of Administration for OxyContin and Comparators Following Introduction of Reformulated...

View Attachment:
Agency Notes: extra pages for readability
 

Exhibit 12 Butler et al Differences in Rates of Abuse and Routes of Administration for Original and Reformulated Extended Release...

View Attachment:

Exhibit 13 Black et al Effects of Reformulated OxyContin Among Patients Assessed for Substance Abuse Treatment in the NAVIPPRO...

View Attachment:
Agency Notes: extra pages for readability
 

Exhibit 14 Butler et al Initial Findings on Abuse Rates and Routes of Administration Among Individuals Assessed for Substance use...

View Attachment:
Agency Notes: extra pages for readability
Publication Reference: 2nd Annual NAVIPPRO Scientific Meeting
 

Exhibit 15 Cassidy et al Initial findings on abuse rates and routes of administration following introduction of reformulated...

View Attachment:
Agency Notes: extra pages for readability
 

Exhibit 16 De Veaugh Geiss et al Routes of Administration and Frequency of Abuse of OxyContin and Immediate Release Oxycodone in...

View Attachment:

Exhibit 17 Leukefeld et al Changes in Prescription and OxyContin Drug Abuse Patterns in a Rural Kentucky County

View Attachment:

Exhibit 18 Perrino et al Evaluation of Abuse Potential of Crushed and Intranasally Administered Oxycodone Tablets

View Attachment:

Exhibit 19 Colucci et al Safety Tolerability and Pharmacokinetics of Crushed Intranasal Oxycodone Tamper Resistant Tablets and...

View Attachment:
Agency Notes: extra pages for readability
 

Exhibit 20 Harris et al Effects of Various Tampering Methods on Exposure to Oxycodone in Healthy Subjects

View Attachment:
Agency Notes: extra pages for readability
 

Exhibit 21 Sellers et al Relative Attractiveness of Reformulated OxyContin Comparative Assessment of Tampering Potential and...

View Attachment:
Agency Notes: extra pages for readability
 

Exhibit 22 Declaration and CV of Edward J Cone PhD with Exhibits A B and C

Reason Restricted: This attachment is restricted to show metadata only because it contains personally identifiable information data.
 

Exhibit 23 Response to Citizen Petitions and Petitions for Stay of Action Docket No 96P 0459

View Attachment:

Exhibit 24 Response to Citizen Petition and Petition for Stay of Action Docket No 93P 0421 Correceted Copy

View Attachment:

Exhibit 25 Letter to The Honorable Leona Aglukkaq Minister of Health Canada From The Honorable Deborah Matthews Minister of Health...

View Attachment:

 
 
Comment Period Closed
ID: FDA-2012-P-0939-0001

Document Information

Date Posted: Oct 24, 2012
Show More Details  

Submitter Information

Submitter's Representative: Kleinfeld, Kaplan and Becker LLP
Category: Private Industry - C0003

Comments

1
Comments Received*
See attached.

Docket Information

This document is contained in
Related Comments:

* This count refers to the total comment/submissions received on this document, as of 11:59 PM yesterday. Note: Agencies review all submissions, however some agencies may choose to redact, or withhold, certain submissions (or portions thereof) such as those containing private or proprietary information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. This can result in discrepancies between this count and those displayed when conducting searches on the Public Submission document type. For specific information about an agency’s public submission policy, refer to its website or the Federal Register document.